| Clinical data | |
|---|---|
| Other names | 17α-Allyltestosterone; 17α-Allylandrost-4-en-17β-ol-3-one |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H32O2 |
| Molar mass | 328.496 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Allyltestosterone, or17α-allyltestosterone, also known as17α-allylandrost-4-en-17β-ol-3-one, is asteroid derived fromtestosterone that was firstsynthesized in 1936 and was never marketed.[1][2] Along withpropyltestosterone (topterone), it has been patented as a topicalantiandrogen and hair growth inhibitor.[2][3] Allyltestosterone is theparent structure of two marketed19-nortestosteroneprogestins,allylestrenol andaltrenogest.[4] These progestins are unique among testosterone derivatives in that they appear to be associated with few or noandrogenic effects.[5][6][7][8]
Other examples are allylestrenol (42), a pro-drug converted to the 3-keto analogue (43), which is used in the treatment of threatened abortion [78,79] and altrenogest (44), used in sows and mares to suppress ovulation and estrus behaviour [80]. [...] Progestins with a 17a-allyl side chain: (42) allylestrenol, (43), (44) altrenogest.